ERBB2 and breast cancer: The SAFIRO2-BREAST IMMUNO trial evaluated the use of durvalumab as a maintenance therapy for HER2-negative breast cancer patients who had undergone 6–8 cycles of chemotherapy without experiencing disease progression.